Qu et al. established a risk stratification model combining clinical variables and routine autoantibodies, with anti-RNP antibody included, and suggested annual screening tests in SLE patients of high PAH risk [10]. The gene discussed is RNPC3; the disease is pulmonary arterial hypertension.